Container Top
Homes   Jobs   Cars   Shopping
Search

Events Calendar

EVENT SEARCH:

In This Section


Most Read Stories


Blogs:


Pets:
First Person: Inside St. Louis Pit Bull Shelter

The Heldenfiles:
Tuesday Notebook

Patrick McManamon:
An interesting thought from a reader

Akron Zips:
Akron vs. Mount Union — Liveblog

Tribe Matters:
Indians announce spring dates

Cleveland Browns:
Mangini doesn't name a quarterback

Kent State Sports:
Flashes interested in another Cincinnati player

Cleveland Cavaliers:
Cavs: Yeah, on That Issue of Privacy

Buckeye Blogging:
Buckeyes Roll 100-60 / Season Outlook

Varsity Letters:
Twinsburg likes chances, but warns offense needs to deliver

All Da King's Men:
More On The Fort Hood Jihadist

Blog of Mass Destruction:
Simply Incapable of Telling The Truth

Akron Law Café:
Health Care Financing Reform: (63) Commonwealth Fund Report on Primary Care

See Jane Style:
Muffle Your Muffler

Car Chase:
Clock Tender- Extending the Life of Collector Car Clocks

Let's Talk Real Estate:
Rumors: Akron Starbucks Closing

Ohio Travels with Betty:
Jack is looking for a trip to Southern Ohio the week of November 16.

Sound Check:
Aeromsith looking for new singer as Steven Tyler contemplates solo career

HRLite House:
Personal Rant – Why People Do Not Live in Northeast Ohio

Akron Gamer:
Video: 'Modern Warfare 2' hits the streets

Defense department grants to spur research in tissue regeneration

By Tracy Wheeler
Beacon Journal medical writer

The Cleveland Clinic will help lead a consortium of institutions in finding new ways to heal soldiers severely wounded in battle, the U.S. Department of Defense announced this afternoon.

The defense department is committing $85 million to create a new Armed Forces Institute for Regenerative Medicine (AFIRM).

The Cleveland Clinic, along with Rutgers University, will head a consortium of 15 research centers that includes Case Western Reserve University, University Hospitals Case Medical Center, the Massachusetts Institute of Technology, Harvard Medical School and the Mayo Clinic, among others.

A second consortium will be led by the University of Pittsburgh and Wake Forest University.

The two research efforts will each receive $42.5 million in grants. The Clinic will receive a $10 million slice of the grant.

The defense department's goal is to push forward research in the areas of tissue regeneration (using a patient's own cells to grow new bone, muscle, tissue, nerves or blood vessels) and transplantation (using donated limbs to replace those lost in battle or donated facial tissue to replace soldiers' faces severely damaged by fire or explosion).

Research in these areas is already taking place — much of it in Cleveland, said Dr. George Muschler, director of the Clinic's clinical tissue-engineering center and co-director of AFIRM.

The goal of the defense department grants is to push the research to make ''dramatic strides in the next one to five years,'' Muschler said.

''The department of defense was very clear that they were not looking for 'pie in the sky' stuff, not things that might be possible 20 years from now,'' he said. ''There are people who need help now. . . . We need to take the things we can do realistically and focus on those first.''

That would include using a patient's own stem cells to regrow bone, muscle and blood vessels lost in an explosion and using limbs from deceased donors to replace hands, feet, arms or legs lost in war.

''This is already a clinical reality,'' said Dr. Maria Siemionow, the Clinic's head of plastic surgery research. ''Fifty patients worldwide have already had hand transplants. Three patients have had partial face transplants.''

The problem with such transplantations, though, is the risk of rejection by the recipient's immune system. Siemionow's research will focus on novel therapies to quell immune response, without forcing the patient to be on immunosuppresive drugs for a lifetime.


Tracy Wheeler can be reached at 330-996-3721 or tawheeler@thebeaconjournal.com.

The Cleveland Clinic will help lead a consortium of institutions in finding new ways to heal soldiers severely wounded in battle, the U.S. Department of Defense announced this afternoon.

The defense department is committing $85 million to create a new Armed Forces Institute for Regenerative Medicine (AFIRM).

The Cleveland Clinic, along with Rutgers University, will head a consortium of 15 research centers that includes Case Western Reserve University, University Hospitals Case Medical Center, the Massachusetts Institute of Technology, Harvard Medical School and the Mayo Clinic, among others.

A second consortium will be led by the University of Pittsburgh and Wake Forest University.

The two research efforts will each receive $42.5 million in grants. The Clinic will receive a $10 million slice of the grant.

The defense department's goal is to push forward research in the areas of tissue regeneration (using a patient's own cells to grow new bone, muscle, tissue, nerves or blood vessels) and transplantation (using donated limbs to replace those lost in battle or donated facial tissue to replace soldiers' faces severely damaged by fire or explosion).

Research in these areas is already taking place — much of it in Cleveland, said Dr. George Muschler, director of the Clinic's clinical tissue-engineering center and co-director of AFIRM.

The goal of the defense department grants is to push the research to make ''dramatic strides in the next one to five years,'' Muschler said.

''The department of defense was very clear that they were not looking for 'pie in the sky' stuff, not things that might be possible 20 years from now,'' he said. ''There are people who need help now. . . . We need to take the things we can do realistically and focus on those first.''

That would include using a patient's own stem cells to regrow bone, muscle and blood vessels lost in an explosion and using limbs from deceased donors to replace hands, feet, arms or legs lost in war.

''This is already a clinical reality,'' said Dr. Maria Siemionow, the Clinic's head of plastic surgery research. ''Fifty patients worldwide have already had hand transplants. Three patients have had partial face transplants.''

The problem with such transplantations, though, is the risk of rejection by the recipient's immune system. Siemionow's research will focus on novel therapies to quell immune response, without forcing the patient to be on immunosuppresive drugs for a lifetime.


Tracy Wheeler can be reached at 330-996-3721 or tawheeler@thebeaconjournal.com.



Story tools

Email  Email   Print  Print   Save  Save   Reprint  Reprint   Popular  Most Popular   Reprint  Subscribe

Share this story

AddThis Social Bookmark Button
















Most Commented Stories